AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29246577 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal repair of myelomeningocele
Number of subjects: 183
Study 29246577 — intervention group
Group type: COMPARATOR
Intervention: Postnatal repair of myelomeningocele
Number of subjects: 183
Study 27883159 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine and must
Number of subjects: 18
Study 27883159 — intervention group
Group type: EXPERIMENTAL
Intervention: Wines higher in melatonin and homovanillic acid
Number of subjects: 18
Study 27883159 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenols in red wine matrix
Number of subjects: 18
Study 25189113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion surgery using a new flexible pedicle screw system (PLIF + 'topping off')
Number of subjects: 0
Study 25189113 — intervention group
Group type: COMPARATOR
Intervention: Conventional fusion surgery (PLIF)
Number of subjects: 0
Study 22250993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC), 3000 mg/day of elemental lanthanum
Number of subjects: 0
Study 20861630 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection (ICDAS)
Number of subjects: 76
Study 20861630 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser fluorescence device (DIAGNOdent pen, LFpen)
Number of subjects: 76
Study 20861630 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiography
Number of subjects: 76
Study 17397870 — intervention group
Group type: EXPERIMENTAL
Intervention: Home anticoagulation testing (HAT)
Number of subjects: 49
Study 17397870 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation clinic service (ACS)
Number of subjects: 49
Study 16222899 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg force-titrated to 80 mg after 1 month (n = 25)
Number of subjects: 75
Study 16222899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg force-titrated to 5 mg after 1 month (n = 25)
Number of subjects: 75
Study 16222899 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg plus Ramipril 2.5 mg (n = 25)
Number of subjects: 75
Study 12470127 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 437
Study 12470127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 9797077 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMS-PCR
Number of subjects: 114
Study 9797077 — intervention group
Group type: COMPARATOR
Intervention: Serology
Number of subjects: 114
Study 7708866 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposuction combined with full abdominoplasty
Number of subjects: 0
Study 7708866 — intervention group
Group type: COMPARATOR
Intervention: Abdominoplasty alone
Number of subjects: 0
Study 2676910 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg per day cyclosporin A (CsA)
Number of subjects: 12
Study 2676910 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 799997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine (25-110 mg/kg per day) for 5-15 days
Number of subjects: 162
Study 799997 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (25-150 mg/kg per day) for 5-15 days
Number of subjects: 162
Study 799997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine and Cephalexin
Number of subjects: 162
Study 31615999 — intervention group
Group type: EXPERIMENTAL
Intervention: Analog computing system with coupled non-linear oscillators
Number of subjects: 0
Study 28044988 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant MitraClip (MC) and left atrial appendage occlusion (LAAO)
Number of subjects: 25
Study 28044988 — intervention group
Group type: COMPARATOR
Intervention: Standalone MitraClip (MC)
Number of subjects: 25
Study 25736975 — intervention group
Group type: EXPERIMENTAL
Intervention: 1700 mg metformin
Number of subjects: 56
Study 25736975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 23578448 — intervention group
Group type: EXPERIMENTAL
Intervention: Flail arm syndrome (FAS) patients
Number of subjects: 56
Study 21690120 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 355
Study 21690120 — intervention group
Group type: COMPARATOR
Intervention: Structured Brief Advice (SBA)
Number of subjects: 355
Study 19794198 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised care model with training on diagnosis and treatment of anxiety disorders and psychiatric consultation-liaison service for 6 months
Number of subjects: 389
Study 19794198 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 389
Study 16798209 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 30
Study 16798209 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 30
Study 12544454 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg indapamide SR
Number of subjects: 0
Study 12544454 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg enalapril
Number of subjects: 0
Study 12544454 — intervention group
Group type: COMPARATOR
Intervention: Placebo run-in
Number of subjects: 0
Study 10839487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 600 mg once daily (OD)
Number of subjects: 569
Study 10839487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg every 12 hours (BD)
Number of subjects: 569
Study 10839487 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 500/125 mg every 8 hours
Number of subjects: 569
Study 8939177 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg, given four times daily for 16 weeks
Number of subjects: 0
Study 8939177 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 200 micrograms, given four times daily for 16 weeks
Number of subjects: 0
Study 8939177 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 1492436 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 100
Study 1492436 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 100
Study 1492436 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 100
Study 1492436 — intervention group
Group type: COMPARATOR
Intervention: AICD (control group)
Number of subjects: 100
Study 3517473 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (Euphyllin retard)
Number of subjects: 11
Study 3517473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31254639 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg twice daily)
Number of subjects: 66
Study 31254639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 28657483 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-initiated clinical encounter cards (CECs) for feedback
Number of subjects: 24
Study 28657483 — intervention group
Group type: COMPARATOR
Intervention: Standard rotations (control group)
Number of subjects: 24
Study 26886383 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 209
Study 26886383 — intervention group
Group type: COMPARATOR
Intervention: Bag Mask Ventilation (BMV)
Number of subjects: 209
Study 25226279 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Asian Diet (TAD)
Number of subjects: 50
Study 25226279 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical Western Diet (TWD)
Number of subjects: 50
Study 22052963 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention using Interactive Voice Response (IVR) system and mobile phones
Number of subjects: 71
Study 20380847 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM accelerometer with web-based tailored PA advice (PAM COACH)
Number of subjects: 87
Study 17021584 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BT‐A) injection at gastrocnemius
Number of subjects: 60
Study 17021584 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BT‐A) injection at adductors
Number of subjects: 60
Study 17021584 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BT‐A) injection at gastrocnemius and adductors
Number of subjects: 60
Study 17021584 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 60
Study 16164922 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (AI) formestane
Number of subjects: 0
Study 16164922 — intervention group
Group type: COMPARATOR
Intervention: Control (no aromatase inhibitor)
Number of subjects: 0
Study 16164922 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibodies)
Number of subjects: 0
Study 12450691 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM+BCG
Number of subjects: 75
Study 12450691 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 75
Study 12450691 — intervention group
Group type: EXPERIMENTAL
Intervention: Three injections of BCG
Number of subjects: 75
Study 10225312 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular waveform pacing
Number of subjects: 32
Study 10225312 — intervention group
Group type: COMPARATOR
Intervention: Square waveform pacing
Number of subjects: 32
Study 10225312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-oesophageal lidocaine 20 mg/ml
Number of subjects: 32
Study 10225312 — intervention group
Group type: COMPARATOR
Intervention: Intra-oesophageal saline
Number of subjects: 32
Study 7880743 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy
Number of subjects: 204
Study 7880743 — intervention group
Group type: COMPARATOR
Intervention: Slightly hypofractionated regimen
Number of subjects: 204
Study 2194128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (400,000 IU of retinyl palmitate, given orally; n = 92)
Number of subjects: 189
Study 2194128 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 97)
Number of subjects: 189
Study 376307 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA) at three different serum levels
Number of subjects: 13
Study 376307 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA)
Number of subjects: 13
Study 31361338 — intervention group
Group type: EXPERIMENTAL
Intervention: Real therapeutic ultrasound
Number of subjects: 40
Study 31361338 — intervention group
Group type: COMPARATOR
Intervention: Sham therapeutic ultrasound
Number of subjects: 40
Study 28329216 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude exposure (4350 m) on Day 0 (D0)
Number of subjects: 11
Study 28329216 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude exposure (4350 m) on Day 2 (D2)
Number of subjects: 11
Study 28329216 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude exposure (4350 m)
Number of subjects: 11
Study 25937443 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmoteplase (90 μg/kg) given 3-9 h after symptom onset
Number of subjects: 492
Study 25937443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 492
Study 25937443 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmoteplase
Number of subjects: 492
Study 23485996 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 196
Study 21056069 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble fiber dextrin (12 g)
Number of subjects: 36
Study 21056069 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble corn fiber (11.8 g)
Number of subjects: 36
Study 21056069 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (11.8 g)
Number of subjects: 36
Study 21056069 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (11.2 g)
Number of subjects: 36
Study 21056069 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic low-fiber preload
Number of subjects: 36
Study 21056069 — intervention group
Group type: COMPARATOR
Intervention: Lower-energy low-fiber preload
Number of subjects: 36
Study 19277873 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management therapy (20 sessions of 2 hours each) and usual health care by a cardiologist
Number of subjects: 247
Study 19277873 — intervention group
Group type: COMPARATOR
Intervention: Usual health care
Number of subjects: 247
Study 16895887 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC activity in activated PBLs
Number of subjects: 7
Study 16895887 — intervention group
Group type: COMPARATOR
Intervention: PCC activity in control PBLs
Number of subjects: 7
Study 15327428 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐halphaGalA (1 mg/kg body weight continuously infused over 4 hours) during dialysis
Number of subjects: 10
Study 15327428 — intervention group
Group type: COMPARATOR
Intervention: r‐halphaGalA (1 mg/kg body weight) administered separately in the interval between dialysis treatments
Number of subjects: 10
Study 15327428 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐flux dialyzer
Number of subjects: 10
Study 11466099 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 (highest vs lowest quartile)
Number of subjects: 550
Study 11466099 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP (highest vs lowest quartile)
Number of subjects: 550
Study 11466099 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 (adjusted for confounders)
Number of subjects: 550
Study 11466099 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP (adjusted for confounders)
Number of subjects: 550
Study 9158882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ormaplatin (30 min intravenous infusion)
Number of subjects: 28
Study 7959280 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphology index scores for malignant ovarian tumors (MI 7.3 +/- 1.9)
Number of subjects: 213
Study 7959280 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of interobserver variation in morphology index scoring
Number of subjects: 213
Study 3669756 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2b-interferon injected subcutaneously 2 X 10(6) IU/m2, three times a week for 12 months.
Number of subjects: 36
Study 3669756 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued treatment with recombinant alpha 2b-interferon for 6 months after initial 12 months.
Number of subjects: 36
Study 3669756 — intervention group
Group type: COMPARATOR
Intervention: No treatment after initial 12 months of interferon therapy.
Number of subjects: 36
Study 31383718 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise (30 minutes/session, 5 days/week)
Number of subjects: 400
Study 31383718 — intervention group
Group type: COMPARATOR
Intervention: High aerobic exercise (60 minutes/session, 5 days/week)
Number of subjects: 400
Study 28681267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen (800 mg in 100 ml normal saline)
Number of subjects: 200
Study 28681267 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paracetamol (1 g in 100 ml normal saline)
Number of subjects: 200
Study 26699692 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained exercises (synergistic wrist and finger exercises with the metacarpophalangeal joint constrained)
Number of subjects: 66
Study 26699692 — intervention group
Group type: COMPARATOR
Intervention: Unconstrained exercises (traditional finger exercises with the metacarpophalangeal joint unconstrained)
Number of subjects: 66
Study 26699692 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained exercises
Number of subjects: 66
Study 26699692 — intervention group
Group type: COMPARATOR
Intervention: Unconstrained exercises
Number of subjects: 66
Study 24080439 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA for 15 min)
Number of subjects: 22
Study 24080439 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS (1 mA for 15 min)
Number of subjects: 22
Study 24080439 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (1 mA for 15 min)
Number of subjects: 22
Study 22371515 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 31506
Study 20569033 — intervention group
Group type: EXPERIMENTAL
Intervention: GSZ
Number of subjects: 26
Study 20569033 — intervention group
Group type: COMPARATOR
Intervention: NZ
Number of subjects: 26
Study 20569033 — intervention group
Group type: EXPERIMENTAL
Intervention: GSZ with neutralizing device
Number of subjects: 26
Study 17652200 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber post placement
Number of subjects: 210
Study 17652200 — intervention group
Group type: COMPARATOR
Intervention: No post placement (Control)
Number of subjects: 210
Study 16081469 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (high-dose combination of calcium, magnesium, zinc, copper, selenium, vitamin A, thiamine, riboflavin, vitamin B6, folate, vitamin B12, vitamin C, vitamin E, vitamin D, Coenzyme Q10) for 9 months
Number of subjects: 30
Study 16081469 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 9 months
Number of subjects: 30
Study 11802135 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 548
Study 11802135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study 10400846 — intervention group
Group type: COMPARATOR
Intervention: 60 mg of fexofenadine HCl twice daily
Number of subjects: 651
Study 10400846 — intervention group
Group type: COMPARATOR
Intervention: 120 mg of sustained‐release pseudoephedrine HCl twice daily
Number of subjects: 651
Study 10400846 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of fexofenadine HCl/120 mg of sustained‐release pseudoephedrine HCl twice daily
Number of subjects: 651
Study 7477169 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus intensive chemotherapy and autologous bone marrow transplantation
Number of subjects: 215
Study 7477169 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without transplantation
Number of subjects: 215
Study 2283674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphygmomat 2 blood pressure monitor
Number of subjects: 49
Study 2283674 — intervention group
Group type: COMPARATOR
Intervention: Hawksley random zero sphygmomanometer
Number of subjects: 49
Study 219470 — intervention group
Group type: EXPERIMENTAL
Intervention: procetofen (3 x 100 mg/day for 4-6 weeks)
Number of subjects: 6
Study 219470 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 31560241 — intervention group
Group type: EXPERIMENTAL
Intervention: Check List for reporting product quality defects
Number of subjects: 338
Study 31560241 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 338
Study 30955220 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hydroxystearic acid (HSA)
Number of subjects: 0
Study 27406859 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato products containing 30 mg lycopene per day
Number of subjects: 79
Study 27406859 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato products plus selenium, omega-3 fatty acids, soy isoflavones, grape/pomegranate juice, and green/black tea (tomato-plus)
Number of subjects: 79
Study 27406859 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 79
Study 27406859 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato products (lycopene)
Number of subjects: 79
Study 25564179 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritonsillar infiltration of ketamine 1.0 mg/kg added to peritonsillar tramadol 2 mg/kg
Number of subjects: 60
Study 25564179 — intervention group
Group type: COMPARATOR
Intervention: Peritonsillar saline and peritonsillar infiltration of tramadol 2 mg/kg
Number of subjects: 60
Study 25528262 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus SCT-based behaviour change intervention
Number of subjects: 0
Study 25528262 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus education intervention
Number of subjects: 0
Study 21181914 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (0-6 month schedule)
Number of subjects: 74
Study 21181914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried blood spots (DBS)
Number of subjects: 74
Study 19793040 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application (clindamycin, dexamethasone)
Number of subjects: 78
Study 19793040 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic application (cefprozil, amoxicillin+clavulanate)
Number of subjects: 78
Study 19793040 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 78
Study 19793040 — intervention group
Group type: COMPARATOR
Intervention: Control (no medications except analgesic)
Number of subjects: 78
Study 17382220 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 12 mg administered 30 minutes or more preoperatively and twice daily postoperatively until hospital discharge (7 or fewer postoperative days)
Number of subjects: 0
Study 17382220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17382220 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 12 mg
Number of subjects: 0
Study 15041504 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol plus acetaminophen (APAP) 37.5 mg tramadol plus 325 mg APAP (n = 98)
Number of subjects: 303
Study 15041504 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol plus acetaminophen (APAP)
Number of subjects: 303
Study 15041504 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 30 mg plus APAP 300 mg (n = 109)
Number of subjects: 303
Study 15041504 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 98)
Number of subjects: 303
Study 15041504 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine plus acetaminophen (APAP)
Number of subjects: 303
Study 11483078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 359
Study 11483078 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (non-treated)
Number of subjects: 359
Study 11483078 — intervention group
Group type: EXPERIMENTAL
Intervention: No ROP group
Number of subjects: 359
Study 11483078 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated eyes (with cryotherapy)
Number of subjects: 359
Study 9710723 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepitel
Number of subjects: 0
Study 9710723 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine
Number of subjects: 0
Study 7905919 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (.05 mg/kg)
Number of subjects: 60
Study 7905919 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam (.25 mg/kg)
Number of subjects: 60